Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Utveckla hjärna, impulsivitet och tvångsförmåga

13 november 2026 uppdaterad av: National Institute of Mental Health (NIMH)

En observationsstudie av den utvecklande hjärnan, impulsivitet och tvångsförmåga.

Background:

Impulsivity is acting 'without thinking.' Compulsivity is being overly inflexible. People vary in how impulsive or compulsive they are. Extreme versions of these behaviors play a role in mental disorders. Researchers want to study changes in the brain to learn more about these behaviors. Differences in genes may also play a role.

Objective:

To learn about genetic & brain features that explain why levels of impulsivity and compulsivity vary across people.

Eligibility:

People ages 6 - 80

Design:

Participants will be screened with a medical history and medical record review.

Participants will talk about their mental and behavioral development. They may discuss topics like drug use and sexual activity. They will complete surveys about their compulsivity and impulsivity. Parents of child participants may also complete these surveys.

Participants may take memory, attention, and thinking tests. They may give blood or saliva samples for gene studies and they may give blood to make induced pluripotent stem cells. Participants may have their face and irises photographs taken.

Participants may have a magnetic resonance imaging scan. It will take pictures of their brain. The scanner is shaped like a cylinder. Participants will lie on a table that slides in and out of the scanner. A coil will be placed over their head. They will lie still, watch a movie, and play a game.

Participants may ask family members to join the study. Researchers are particularly interested in recruiting twin pairs to the study.

Participants under age 25 may repeat these tests every 1-2 years until they turn 25 or until the study ends. For those over age 25, participation will last less than 1 month.

Studieöversikt

Detaljerad beskrivning

Study Description:

Many neuropsychiatric disorders have extreme impairing impulsivity and compulsivity behaviors at their core. We hypothesized that the development of symptoms of impulsivity and compulsivity during childhood/adolescence and early adulthood will be associated with atypical trajectories of brain features including cortical glutamate (the main excitatory neurotransmitter) and functional/structural brain connectivity. Additionally, we hypothesize that cortical glutamate will be under genetic control (i.e., heritable) and that common genetic variant risk for disorders characterized by extreme impulsivity (e.g., attention deficit hyperactivity disorder) and by extreme compulsivity (e.g., obsessive compulsive disorder, autism spectrum disorder) will also be associated with atypical cortical glutamate trajectories. To elucidate the relationships between the developing brain, compulsivity/impulsivity and genomics, we will collect clinical assessments including clinician-led interviews, neurobehavioral assessments, neuroimaging data, and genomic samples using 1) a prospective longitudinal design to answer developmental hypotheses; 2) a twin design to assess heritability hypotheses.

Objectives:

Primary Objective:

A) To assess the effects of impulsivity and compulsivity on the developmental trajectories of cortical glutamate.

B) To determine the heritability of cortical glutamate.

Secondary Objectives:

A) To establish the reliability of glutamate measurements.

B) To examine the impact of atypical glutamate levels on developing structural and functional connections within the fronto-striatal circuits.

C) To assess within twin pair differences in neurodevelopmental markers (cortical glutamate, structural/functional MRI) in relation to differences in symptom domains.

Endpoints:

Primary Endpoint:

A) Age-related change in cortical glutamate levels and its moderation by individual differences in levels of impulsivity and compulsivity.

B) Heritability of cortical glutamate (proportion of variance explained by additive genetic factors).

Secondary Endpoints:

A) 1) Glutamate levels estimated at 3 Tesla at short intervals to establish test-retest reliability.

2) Glutamate levels estimated at both 3 Tesla and 7 Tesla (cross scanner validation).

B) Measures of the brain's structural and functional connectivity.

C) Within twin-pair differences in neurodevelopmental markers symptom domains (impulsivity/compulsivity).

Studietyp

Observationell

Inskrivning (Beräknad)

1100

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Maryland
      • Bethesda, Maryland, Förenta staterna, 20892
        • Rekrytering
        • National Institutes of Health Clinical Center
        • Kontakt:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • Telefonnummer: TTY8664111010 800-411-1222
          • E-post: prpl@cc.nih.gov

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

6 år till 80 år (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Individuals between 6 and 80 years of age with a wide range of impulsivity/compulsivity behaviors - ranging from normal to mildly/extremely impaired - will be recruited. No specific demographic groups will be targeted. Recruitment will be mainly done in the District of Columbia/Maryland/Virginia area, however some participants might travel from elsewhere.

Beskrivning

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Stated willingness to comply with all study procedures and availability for the duration of the study.
  2. Must be between 6 and 80 years of age.
  3. Ability of participant to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Cognitively not capable of performing study procedures or lack of capacity to provide informed consent. Indications of a lack of cognitive capacity could include a known full-scale IQ under 70, or a history from the screening interview that implies global intellectual disabilities (e.g., placement in a school for children with intellectual disability etc.)
  2. Very premature birth (i.e., birth before 32 weeks of gestational age).
  3. Any known brain abnormalities (e.g., tumor, periventricular leukomalacia, microcephaly) or history of medical conditions known to affect cerebral anatomy (e.g., epilepsy, history of stroke, head injury with a loss of consciousness of one hour or more).
  4. Psychotic disorders (including schizophrenia, psychosis not otherwise specified).
  5. Dementia, or other conditions that, in the opinion of the investigators, would impede compliance or possibly hinder completion of the study.
  6. Pregnant women.
  7. Any other medical or psychiatric condition that in the opinion of the PI may confound study data/assessments.

Additional exclusion criteria for optional MRI procedure:

1. Individuals who are not able to receive an MRI (e.g., metal bioimplants, claustrophobia, inability to lie flat on their backs, pregnant women, and any other contraindications for MRI scanning according to the NMR Center MRI safety guidelines).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
impulsive compulsive

Individuals between 6 and 80 years of age with a wide range of impulsivity/compulsivity behaviors - ranging from normal to mildly/extremely impaired.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Glutamate concentration measured using Magnetic Resonance Spectroscopy
Tidsram: Yearly if possible

Age-related change in cortical glutamate levels and its moderation by individual differences in levels of impulsivity and compulsivity.

Yearly if possible
Heritability of cortical glutamate (proportion of variance explained by additive genetic factors).
Tidsram: Baseline

Degree to which glutamate levels are under genetic control.

Baseline

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Structural and functional connectivity
Tidsram: Yearly if possible

Structural and functional connectivity measured throughout development using Magnetic Resonance Imaging.

Yearly if possible
Glutamate levels
Tidsram: weeks to months

Glutamate measurement at 7 Tesla is now the gold standard for glutamate measurements, against which we will compare measurements at 3 Tesla.

weeks to months
Differences in glutamate levels and other neurodevelopmental markers within twin pairs.
Tidsram: Yearly if possible

Differences in twin characteristics will be measured through clinical symptom assessment, biomarkers, Magnetic Resonance Imaging, neuropsychological testing, and questionnaires.

Yearly if possible

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Tonya J White, M.D., National Institute of Mental Health (NIMH)

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

30 september 2022

Primärt slutförande (Beräknad)

31 december 2030

Avslutad studie (Beräknad)

31 december 2031

Studieregistreringsdatum

Först inskickad

14 november 2020

Först inskickad som uppfyllde QC-kriterierna

14 november 2020

Första postat (Faktisk)

17 november 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2026

Senast verifierad

12 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All de-identified medical information will be placed in a NIH repository (e.g., Biomedical Translational Research Information System (BTRIS)) in accordance to NIH policies. We will also share genomic and phenotypic data in controlled access databases such as dbGAP (database of Genotypes and Phenotypes). Other databases may be used as approved by NIH for the sharing of de-identified data.

Tidsram för IPD-delning

The timeline for data sharing will follow the NHGRI Genomic Data Sharing Policy. Currently data is deposited following IRB review once the study data collection is complete and the data has undergone quality control steps.

Kriterier för IPD Sharing Access

Access requests for specific research purposes using NIH controlled-access data are reviewed by NIH Data Access Committees (DACs).

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera